Obalon Therapeutics Profit Margin

The latest profit margin for OBLN is 1539.01% as of March 2026. That compares with -47.81% in the prior-year period — up 3318.7% year over year. That is above the Healthcare sector average of 14.34%. Investors often review this figure alongside Obalon Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, OBLN's profit margin moved from -47.81% to 1539.01% — a 3318.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Obalon Therapeutics's valuation or profitability profile.

Against Healthcare companies, OBLN currently prints 1539.01% for profit margin, while the sector average sits near 14.34%. That is roughly 10628.7% above the sector mean. Large gaps often invite a closer look at Obalon Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Obalon Therapeutics converts resources into returns. At 1539.01%, OBLN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -47.81% in the prior-year period — up 3318.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting OBLN's profit margin (1539.01%), review year-over-year change from -47.81%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.